Markets
Hims & Hers Big Game commercial
A screenshot of Hims & Hers’ 2025 Super Bowl commercial (Sherwood News)

Hims slips after US lawmakers introduce bill cracking down on compounding

Analysts at Citi said that the bill presents a headwind for Hims.

J. Edward Moreno

Hims & Hers slipped on Wednesday after members of Congress introduced a bill that would limit its ability to sell copies of blockbuster weight-loss drugs made by Eli Lilly and Novo Nordisk.

The bill, “Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025,” is sponsored by Rep. Rudy Yakym III and Rep. Andre Carson, both of Indiana, where Lilly is headquartered. The bill would raise the bar for when it is legal to dispense compounded versions of popular weight-loss drugs, an industry that has exploded in the past couple of years.

Analysts at Citi said that the bill presents a headwind for Hims. It would “significantly curtail [Hims’] ability to compound GLP-1s,” the product category where the company has seen the most revenue growth in the past year, the analysts said in a Wednesday morning note.

Under federal law, compounding pharmacies can sell exact copies of a branded medication only when it is in a shortage. Lilly and Novo’s GLP-1s were taken off the Food and Drug Administration’s shortage list earlier this year, meaning compounding pharmacies could only continue selling bespoke versions for individual patients.

Telehealth companies like Hims have continued to market compounded GLP-1s, often referring to them “personalized.” The bill would raise the bar for when that is allowed, requiring a doctor to determine whether a compounded version creates a “significant difference” over the commercially available version sold by drugmakers.

The drugmakers have pushed back on telehealth companies’ claim of “personalization,” arguing that the drugs are mass produced and not made for specific patients like the law intends. Lilly and Novo have taken some of these companies to court, and have for the most part lost. The drugmakers have also urged the FDA to up enforcement, but it shares regulatory responsibility with a patchwork of state regulators.

The SAFE Act may empower the FDA to crack down on compounders, which have been nibbling away at drugmakers’ market share.

Hims did not immediately respond to a request for comment.

More Markets

See all Markets
markets

United beats Q1 earnings and revenue estimates, lowers full-year profit guidance amid surging jet fuel prices

United Airlines reported its first-quarter earnings results after the bell on Tuesday. The carrier’s shares ticked down in after-hours trading.

For Q1, United reported:

  • Adjusted earnings of $1.19 per share, compared to the Wall Street estimate of $1.08 per share compiled by FactSet.

  • $14.6 billion in revenue, compared to the $14.39 billion consensus estimate.

In the first quarter, United’s fuel expense grew 12.6% from the same period last year to $3.04 billion.

For the second quarter, United expects adjusted earnings per share of between $1 and $2, shy of Wall Street expectations of $2.08. For the full year ahead, United said it expects earnings between $7 and $11 per share, compared to its prior guidance of between $12 and $14 per share.

“Guidance assumes United’s revenue recovers 40% to 50% of the fuel price increases in the second quarter, 70% to 80% of the fuel price increases in the third quarter and 85% to 100% of the fuel price increases in the fourth quarter 2026,” read the company’s investor update.

Earlier this month, United was among the first major US airlines to hike its bag fees amid higher fuel costs. Its shares have fallen more than 15% from a February high days before the war in Iran began.

United has also made waves this month following reports that CEO Scott Kirby had floated the idea of a merger with American Airlines to President Trump. A merger between two of the big four airlines would create a true US behemoth, controlling more than a third of the American market. American Air last week said it wasn’t interested in merging with United and hadn’t held talks on the idea. On Tuesday, Trump told CNBC that he doesn’t like the idea either.

markets

Hedge funds are following retail traders into the Magnificent 7

Hedge funds are following retail traders into the stocks the masses never stopped buying.

“As we kick off earnings for megacap tech stocks, this stood out: [hedge funds] have started buying Mag7 stocks again this month though positioning remains well below the peak levels seen in early 2016,” wrote Goldman Sachs’ Cullen Morgan.

Goldman PB Mag 7
Source: Goldman Sachs

In early April, JPMorgan strategist Arun Jain noted that retail investors had basically been selling everything but the Magnificent 7 stocks as part of a more cautious stance due to the Iran war.

(Apple has been a long-standing exception to this trend, presumably because retail traders arent fond of its hands-off approach to AI.)

JPM Retail flows

Last August, Jain discussed how retail activity tended to “crowd in” institutional buyers in meme stocks, while Goldman’s John Marshall advised clients to piggyback on stocks beloved by retail traders. Speculative, retail-geared assets proceeded to go on a tremendous run that soured in October.

But there are some early indications that a similar bout of speculative fervor is bubbling up once more.

markets

POET Technologies surges above $10 for first time in 4 years amid explosion in call volumes

POET Technologies is up nearly 40% this week as options market activity goes haywire in a faint echo of what got the stock on retail traders’ radars in October.

As of 11:12 a.m. ET, more than 10 calls have changed hands for every put traded. This bullish impulse has propelled the stock above the $10 threshold for the first time since March 2022.

Shares of the optical communications firm briefly dipped last week after Wolfpack Research said it was short the company because its investors would be exposed to an “IRS tax nightmare.”

The company responded that day saying it was taking measures for US shareholders that “should mitigate certain potential adverse US federal income tax consequences to it that could otherwise result from the Company’s status as a passive foreign investment company.”

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.